Losing participants before the trial ends erodes credibility of findings
Xia, Jun Adams, Clive E.
Xia, Jun
Adams, Clive E.
Abstract
AIMS AND METHOD: To estimate the proportion of attrition at which results of drug trials for people with schizophrenia lose enough credibility to become mistrusted by relevant groups of stakeholders. A piloted questionnaire was sent to 128 local clinicians, 100 relevant researchers and 104 service users and carers.
RESULTS: We received the biggest number of responses from the service user and carer group (n=81, 76%); 43% of clinicians and 32% of researchers responded. All three groups suggested that the follow-up rate for a 12-week schizophrenia drug trial should be around 70-75% for the trial to be credible.
CLINICAL IMPLICATIONS: This survey suggests that relevant stakeholders, including researchers, fundamentally mistrust results of the majority of drug trials in schizophrenia. Adopting a more pragmatic trial design can help address this.
MIDER Authors
Affiliations
Citations
Altmetric:
Date
2009
Type
Article
Subject
Collections
Citation
Xia, J., Adams, C. E., Bhagat, N., Bhagat, V., Bhoopathi, P., El-Sayeh, H., Pinfold, V. & Takriti, Y. (2009). Losing participants before the trial ends erodes credibility of findings. Psychiatric Bulletin, 33 (7), pp.254-257.